Who are Abiraterone Acetate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NIRAPARIB, Abiraterone acetate and prednisone, Abiraterone Acetate (AA), Fuzuloparib , Abiraterone acetate and Prednisone, Abiraterone Acetate or Enzalutamide, Abiraterone + Prednisolone/Prednisone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abiraterone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Abiraterone Acetate — Competitive Intelligence Brief

Abiraterone Acetate (abiraterone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen biosynthesis inhibitor. Area: Oncology.

marketed Androgen biosynthesis inhibitor CYP17 Oncology Live · refreshed every 30 min

Target snapshot

Abiraterone Acetate (abiraterone) — Pfizer. Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abiraterone Acetate TARGET	abiraterone	Pfizer	marketed	Androgen biosynthesis inhibitor	CYP17	2011-01-01
NIRAPARIB	NIRAPARIB		marketed		PARP-1, PARP-2, CYP17	2017-01-01
Abiraterone acetate and prednisone	Abiraterone acetate and prednisone	Janssen Research & Development, LLC	phase 3	CYP17A1 inhibitor (androgen synthesis inhibitor)	CYP17A1 (17α-hydroxylase/17,20-lyase)
Abiraterone Acetate (AA)	Abiraterone Acetate (AA)	Janssen Research & Development, LLC	phase 3	CYP17A1 inhibitor	CYP17A1 (17α-hydroxylase/17,20-lyase)
Fuzuloparib , Abiraterone acetate and Prednisone	Fuzuloparib , Abiraterone acetate and Prednisone	Jiangsu HengRui Medicine Co., Ltd.	phase 3	PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone)	PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone)
Abiraterone Acetate or Enzalutamide	Abiraterone Acetate or Enzalutamide	National Cancer Institute, Naples	phase 3	Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide)	CYP17A1 (abiraterone) / Androgen receptor (enzalutamide)
Abiraterone + Prednisolone/Prednisone	Abiraterone + Prednisolone/Prednisone	AstraZeneca	phase 3	CYP17A1 inhibitor (androgen synthesis inhibitor) + glucocorticoid	CYP17A1 (17α-hydroxylase/17,20-lyase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen biosynthesis inhibitor class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abiraterone Acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab